tiprankstipranks
Trending News
More News >
Insmed (INSM)
NASDAQ:INSM
US Market
Advertisement

Insmed (INSM) Stock Forecast & Price Target

Compare
976 Followers
See the Price Targets and Ratings of:

INSM Analyst Ratings

Strong Buy
19Ratings
Strong Buy
17 Buy
2 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Insmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

INSM Stock 12 Month Forecast

Average Price Target

$155.06
▲(13.16% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $155.06 with a high forecast of $240.00 and a low forecast of $110.00. The average price target represents a 13.16% change from the last price of $137.03.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"$67","154":"$154","241":"$241","110.5":"$110.5","197.5":"$197.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":155.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$155.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,110.5,154,197.5,241],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,145.3,152.5846153846154,159.86923076923077,167.15384615384616,174.43846153846155,181.72307692307692,189.0076923076923,196.2923076923077,203.5769230769231,210.86153846153846,218.14615384615385,225.43076923076922,232.7153846153846,{"y":240,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,145.3,146.05076923076925,146.80153846153848,147.5523076923077,148.30307692307693,149.05384615384617,149.8046153846154,150.5553846153846,151.30615384615385,152.05692307692308,152.80769230769232,153.55846153846153,154.30923076923077,{"y":155.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,145.3,142.5846153846154,139.86923076923077,137.15384615384616,134.43846153846155,131.72307692307692,129.0076923076923,126.2923076923077,123.57692307692308,120.86153846153846,118.14615384615385,115.43076923076923,112.71538461538461,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.62,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$240.00Average Price Target$155.06Lowest Price Target$110.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on INSM
Wells Fargo
Wells Fargo
$171
Buy
24.79%
Upside
Reiterated
09/26/25
Wells Fargo Sticks to Their Buy Rating for Insmed (INSM)
RBC Capital Analyst forecast on INSM
RBC Capital
RBC Capital
$138
Buy
0.71%
Upside
Reiterated
09/19/25
Insmed (INSM) Receives a Buy from RBC Capital
J.P. Morgan Analyst forecast on INSM
J.P. Morgan
J.P. Morgan
$135$153
Buy
11.65%
Upside
Reiterated
09/09/25
J.P. Morgan Keeps Their Buy Rating on Insmed (INSM)
Leerink Partners Analyst forecast on INSM
Leerink Partners
Leerink Partners
$180
Buy
31.36%
Upside
Reiterated
09/08/25
Promising Market Potential for Insmed's Brensocatib Drives Buy RatingWe are reiterating our OP rating and $180 PT.
Guggenheim Analyst forecast on INSM
Guggenheim
Guggenheim
$125$172
Buy
25.52%
Upside
Reiterated
09/05/25
Guggenheim Keeps Their Buy Rating on Insmed (INSM)Insmed price target raised to $172 from $125 at Guggenheim
Bank of America Securities Analyst forecast on INSM
Bank of America Securities
Bank of America Securities
$142
Buy
3.63%
Upside
Reiterated
09/02/25
Insmed's Growth Potential Highlighted by TPIP's Market Opportunity and Positive Outlook
Mizuho Securities Analyst forecast on INSM
Mizuho Securities
Mizuho Securities
$165
Buy
20.41%
Upside
Reiterated
09/02/25
Mizuho Securities Keeps Their Buy Rating on Insmed (INSM)with our current $165 PT implying 21% upside from last Friday's close (and IPF not yet modeled), we reiterate our OP rating on INSM.
Morgan Stanley Analyst forecast on INSM
Morgan Stanley
Morgan Stanley
$144
Hold
5.09%
Upside
Reiterated
09/02/25
Cautious Hold Rating on Insmed Amid Positive IPF Trial Results and Awaited Strategic Clarity
Stifel Nicolaus Analyst forecast on INSM
Stifel Nicolaus
Stifel Nicolaus
$121$145
Buy
5.82%
Upside
Reiterated
09/02/25
Optimistic Buy Rating for Insmed's TPIP Driven by Promising TETON-2 Trial Results and Market Potential in IPF Treatment
William Blair Analyst forecast on INSM
William Blair
William Blair
Buy
Reiterated
09/02/25
Buy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development
Evercore ISI
$90$110
Buy
-19.73%
Downside
Initiated
08/22/25
Evercore ISI Sticks to Their Buy Rating for Insmed (INSM)
TR | OpenAI - 4o Analyst forecast on INSM
TR | OpenAI - 4o
TR | OpenAI - 4o
$121$135
Hold
-1.48%
Downside
Reiterated
08/20/25
AI Generated ArticleAI Generated Article
Wolfe Research Analyst forecast on INSM
Wolfe Research
Wolfe Research
$109$173
Buy
26.25%
Upside
Reiterated
08/14/25
Wolfe Research Sticks to Their Buy Rating for Insmed (INSM)Wolfe Research analyst Andy Chen raised the price target on Insmed (NASDAQ: INSM) to $173.00 (from $109.00) while maintaining a Outperform rating.
Truist Financial Analyst forecast on INSM
Truist Financial
Truist Financial
$126$139
Buy
1.44%
Upside
Reiterated
08/14/25
Truist Financial Sticks to Its Buy Rating for Insmed (INSM)
TD Cowen Analyst forecast on INSM
TD Cowen
TD Cowen
$135$154
Buy
12.38%
Upside
Reiterated
08/13/25
Insmed's Brensocatib Approval Boosts Market Potential and Stock Valuation
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on INSM
Wells Fargo
Wells Fargo
$171
Buy
24.79%
Upside
Reiterated
09/26/25
Wells Fargo Sticks to Their Buy Rating for Insmed (INSM)
RBC Capital Analyst forecast on INSM
RBC Capital
RBC Capital
$138
Buy
0.71%
Upside
Reiterated
09/19/25
Insmed (INSM) Receives a Buy from RBC Capital
J.P. Morgan Analyst forecast on INSM
J.P. Morgan
J.P. Morgan
$135$153
Buy
11.65%
Upside
Reiterated
09/09/25
J.P. Morgan Keeps Their Buy Rating on Insmed (INSM)
Leerink Partners Analyst forecast on INSM
Leerink Partners
Leerink Partners
$180
Buy
31.36%
Upside
Reiterated
09/08/25
Promising Market Potential for Insmed's Brensocatib Drives Buy RatingWe are reiterating our OP rating and $180 PT.
Guggenheim Analyst forecast on INSM
Guggenheim
Guggenheim
$125$172
Buy
25.52%
Upside
Reiterated
09/05/25
Guggenheim Keeps Their Buy Rating on Insmed (INSM)Insmed price target raised to $172 from $125 at Guggenheim
Bank of America Securities Analyst forecast on INSM
Bank of America Securities
Bank of America Securities
$142
Buy
3.63%
Upside
Reiterated
09/02/25
Insmed's Growth Potential Highlighted by TPIP's Market Opportunity and Positive Outlook
Mizuho Securities Analyst forecast on INSM
Mizuho Securities
Mizuho Securities
$165
Buy
20.41%
Upside
Reiterated
09/02/25
Mizuho Securities Keeps Their Buy Rating on Insmed (INSM)with our current $165 PT implying 21% upside from last Friday's close (and IPF not yet modeled), we reiterate our OP rating on INSM.
Morgan Stanley Analyst forecast on INSM
Morgan Stanley
Morgan Stanley
$144
Hold
5.09%
Upside
Reiterated
09/02/25
Cautious Hold Rating on Insmed Amid Positive IPF Trial Results and Awaited Strategic Clarity
Stifel Nicolaus Analyst forecast on INSM
Stifel Nicolaus
Stifel Nicolaus
$121$145
Buy
5.82%
Upside
Reiterated
09/02/25
Optimistic Buy Rating for Insmed's TPIP Driven by Promising TETON-2 Trial Results and Market Potential in IPF Treatment
William Blair Analyst forecast on INSM
William Blair
William Blair
Buy
Reiterated
09/02/25
Buy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development
Evercore ISI
$90$110
Buy
-19.73%
Downside
Initiated
08/22/25
Evercore ISI Sticks to Their Buy Rating for Insmed (INSM)
TR | OpenAI - 4o Analyst forecast on INSM
TR | OpenAI - 4o
TR | OpenAI - 4o
$121$135
Hold
-1.48%
Downside
Reiterated
08/20/25
AI Generated ArticleAI Generated Article
Wolfe Research Analyst forecast on INSM
Wolfe Research
Wolfe Research
$109$173
Buy
26.25%
Upside
Reiterated
08/14/25
Wolfe Research Sticks to Their Buy Rating for Insmed (INSM)Wolfe Research analyst Andy Chen raised the price target on Insmed (NASDAQ: INSM) to $173.00 (from $109.00) while maintaining a Outperform rating.
Truist Financial Analyst forecast on INSM
Truist Financial
Truist Financial
$126$139
Buy
1.44%
Upside
Reiterated
08/14/25
Truist Financial Sticks to Its Buy Rating for Insmed (INSM)
TD Cowen Analyst forecast on INSM
TD Cowen
TD Cowen
$135$154
Buy
12.38%
Upside
Reiterated
08/13/25
Insmed's Brensocatib Approval Boosts Market Potential and Stock Valuation
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

1 Month
xxx
Success Rate
14/22 ratings generated profit
64%
Average Return
+14.18%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +14.18% per trade.
3 Months
xxx
Success Rate
19/24 ratings generated profit
79%
Average Return
+35.35%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 79.17% of your transactions generating a profit, with an average return of +35.35% per trade.
1 Year
Andrew FeinH.C. Wainwright
Success Rate
14/14 ratings generated profit
100%
Average Return
+116.21%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +116.21% per trade.
2 Years
xxx
Success Rate
14/14 ratings generated profit
100%
Average Return
+217.34%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +217.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INSM Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
6
6
5
1
1
Buy
32
36
34
51
47
Hold
6
10
7
12
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
44
52
46
64
56
In the current month, INSM has received 48 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. INSM average Analyst price target in the past 3 months is 155.06.
Each month's total comprises the sum of three months' worth of ratings.

INSM Financial Forecast

INSM Earnings Forecast

Next quarter’s earnings estimate for INSM is -$1.34 with a range of -$1.67 to -$1.11. The previous quarter’s EPS was -$1.70. INSM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.14% of the time in the same period. In the last calendar year INSM has Preformed in-line its overall industry.
Next quarter’s earnings estimate for INSM is -$1.34 with a range of -$1.67 to -$1.11. The previous quarter’s EPS was -$1.70. INSM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.14% of the time in the same period. In the last calendar year INSM has Preformed in-line its overall industry.

INSM Sales Forecast

Next quarter’s sales forecast for INSM is $114.72M with a range of $106.00M to $121.97M. The previous quarter’s sales results were $107.42M. INSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 72.41% of the time in the same period. In the last calendar year INSM has Outperformed its overall industry.
Next quarter’s sales forecast for INSM is $114.72M with a range of $106.00M to $121.97M. The previous quarter’s sales results were $107.42M. INSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 72.41% of the time in the same period. In the last calendar year INSM has Outperformed its overall industry.

INSM Stock Forecast FAQ

What is INSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Insmed’s 12-month average price target is 155.06.
    What is INSM’s upside potential, based on the analysts’ average price target?
    Insmed has 13.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is INSM a Buy, Sell or Hold?
          Insmed has a consensus rating of Strong Buy which is based on 17 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Insmed’s price target?
            The average price target for Insmed is 155.06. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $240.00 ,the lowest forecast is $110.00. The average price target represents 13.16% Increase from the current price of $137.03.
              What do analysts say about Insmed?
              Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of INSM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis